ProCE Banner Activity

CME

Current and Emerging CAR T-Cell Therapies in Cancer Care

Multimedia
In this interactive webcast from a live CCO webinar, experts discuss the latest data on safely and effectively leveraging CAR T-cell therapies for treating patients with diverse hematologic malignancies.

Physicians: Maximum of 1.75 AMA PRA Category 1 Credits

Released: July 09, 2021

Expiration: July 08, 2022

No longer available for credit.

Share

Faculty

Caron Jacobson

Caron Jacobson, MD

Associate Professor of Medicine
Harvard Medical School
Medical Director, Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Jae H. Park

Jae H. Park, MD

Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York

Noopur Raje

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Target Audience

This program is intended for physicians and other healthcare providers who treat and manage patients with leukemia, lymphoma, or myeloma who are candidates for CAR T-cell therapies.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify patients who are eligible and most likely to benefit from CAR T-cell therapy
  • Integrate into practice clinical trial data on CAR T-cell–based therapies for the treatment of patients with leukemia and lymphoma
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
  • Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
  • Appraise ongoing clinical trials evaluating CAR T-cell therapy for the treatment of patients with hematologic malignancies and solid tumors

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Caron Jacobson, MD

Associate Professor of Medicine
Harvard Medical School
Medical Director, Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Caron A. Jacobson, MD, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb/Celgene, Bluebird Bio, Kite, Lonza, Nkarta, Novartis, and Precision Biosciences; and funds for research support from Kite.

Jae H. Park, MD

Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York

Jae H. Park, MD, has disclosed that he has received consulting fees from Affyimmune, Amgen, Artiva, AstraZeneca, Autolus, Bristol Myers Squibb, Curocel, Innate, Intellia, Kite, Kura Oncology, Novartis, Pfizer, Servier, Takeda, and Umoja.

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Noopur Raje, MD, has disclosed that she has received funds for research support from Bluebird and consulting fees from Amgen, Bristol-Myers Squibb, Caribou, Celgene, Immuneel, Karyopharm, and Takeda.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 09, 2021, through July 08, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare providers so they can confidently and competently integrate CAR T-cell therapy into their clinical practices.